IP-10dp Peptide Inhibits Angiogenesis via CXCR3-B Receptor Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inhibiting angiogenesis in cancer treatment are not highly effective in preventing tumor malignancy and metastasis, and there is a need for non-toxic treatments that can effectively target endothelial cell function to inhibit vessel formation and promote wound healing.
Innovation Solution
Development of peptides derived from the C-terminal α-helix region of Interferon gamma-induced protein 10 (IP-10), specifically a 21-amino acid fragment known as IP-10dp, which binds and activates the CXCR3-B receptor to inhibit endothelial cell motility and vessel formation, and induces vessel dissociation, thereby inhibiting angiogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current angiogenesis inhibition therapies are used in cancer treatment, then tumor growth may be slowed, but they are not highly effective in preventing tumor malignancy and metastasis and may cause toxicity
Solution Approach 1:
The invention segments the full-length IP-10 chemokine into smaller peptide fragments, specifically the C-terminal alpha-helix region (amino acids 78-98). This segmentation creates peptides that retain the ability to bind CXCR3 receptors and inhibit angiogenesis while potentially reducing the toxicity associated with full-length chemokine therapies. The segmented peptide approach allows for targeted delivery and reduced off-target effects.
Solution Approach 2:
The invention extracts the critical functional region (C-terminal alpha-helix) from the full IP-10 molecule. This extracted peptide fragment contains the essential amino acid sequence (PESKAIKNLLKAVSKEMSKRSP) needed for CXCR3 receptor binding and angiogenesis inhibition, while eliminating non-essential portions that may contribute to toxicity. The extraction principle isolates the therapeutic active site for optimized treatment.
2Reliability
If full-length IP-10 is used to inhibit angiogenesis, then endothelial cell function is targeted, but the peptide size may limit delivery efficiency and tissue penetration
Solution Approach 1:
The full-length IP-10 protein (28 amino acids) is segmented into a smaller C-terminal alpha-helix peptide (21 amino acids, residues 78-98). This segmentation reduces the peptide length from the full protein size to a compact fragment that maintains angiogenesis inhibition activity while improving delivery efficiency and tissue penetration capabilities.
Solution Approach 2:
The critical C-terminal alpha-helix region (amino acids 78-98) is extracted from the full IP-10 molecule. This extracted peptide sequence (PESKAIKNLLKAVSKEMSKRSP) retains the essential receptor-binding capability while being significantly smaller and more deliverable than the full-length chemokine, overcoming delivery efficiency limitations.
3Reliability
If angiogenesis is inhibited to prevent tumor growth, then vessel formation is reduced, but wound healing processes that require angiogenesis may be impaired
Solution Approach 1:
The IP-10dp peptide therapy exhibits local quality by selectively inhibiting pathological angiogenesis in tumor environments while preserving physiological angiogenesis in wound healing sites. The peptide targets CXCR3-expressing endothelial cells in tumors through localized administration, allowing normal wound repair processes in other tissues to proceed unaffected. This spatial selectivity resolves the contradiction between anti-tumor and pro-healing requirements.
Solution Approach 2:
The invention inverts the traditional approach by using a chemokine-derived peptide that naturally inhibits angiogenesis but can be selectively deployed. Instead of using broad-spectrum anti-angiogenic drugs that impair all vessel formation, the IP-10dp peptide is administered locally to tumors, inverting the problem-solution dynamic: the same mechanism that could harm wound healing is instead used to protect healthy tissue while attacking cancer through targeted delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
IP-10dp effectively inhibits endothelial cell migration and tube formation in vitro and in vivo, demonstrating potent anti-angiogenic activity similar to full-length IP-10, with the ability to induce vessel regression and promote wound healing by targeting CXCR3 receptors.
Implementation Method 1
IP-10dp binds and activates the CXCR3-B receptor to inhibit endothelial cell motility and vessel formation, and induces vessel dissociation
Data Source
AI summary
Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the α-helix portion IP-10 (CXCL10) or from IP-9 (CXCL11), are nontoxic, and smaller than naturally occurring peptides, making them useful in therapies against diseases or disease states marked by unwanted angiogenesis, including tumorogenic diseases such as cancers, and in healing of chronic wounds.